# Limited Adjuvant Endocrine Therapy for Low Risk Breast Cancer

> **NCT03917082** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **British Columbia Cancer Agency** · enrollment: 290 (estimated)

## Conditions studied

- Breast Cancer Female
- Hormone Receptor Positive Tumor

## Interventions

- **DRUG:** Tamoxifen Citrate

## Key facts

- **NCT ID:** NCT03917082
- **Lead sponsor:** British Columbia Cancer Agency
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-09-23
- **Primary completion:** 2026-05-01
- **Final completion:** 2029-05-01
- **Target enrollment:** 290 (ESTIMATED)
- **Last updated:** 2023-06-15

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03917082

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03917082, "Limited Adjuvant Endocrine Therapy for Low Risk Breast Cancer". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT03917082. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*